{"id":952514,"date":"2026-04-17T08:34:22","date_gmt":"2026-04-17T12:34:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified\/"},"modified":"2026-04-17T08:34:22","modified_gmt":"2026-04-17T12:34:22","slug":"intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified\/","title":{"rendered":"Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified"},"content":{"rendered":"

\nINBS implements enhanced security architecture to protect test integrity and donor data, strengthening upcoming FDA 510(k) submission
\n<\/h2>\n
\n

NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of penetration testing as part of its upcoming FDA 510(k) submission. The testing identified no major vulnerabilities, verified the robustness of the Company’s existing security infrastructure, and strengthened its regulatory submission to the FDA.<\/p>\n

In conjunction with the penetration testing, INBS implemented additional security upgrades to its drug testing technology. These upgrades include enhanced encrypted identification tags to ensure test integrity and improved firmware safeguards that allow only authorized updates and protect against cyber threats.<\/p>\n

\n “Successful completion of penetration testing is another key milestone in our FDA 510(k) submission process. This independent assessment identified no major security vulnerabilities, confirming the effectiveness of our security approach,\u201d said Harry Simeonidis, President and CEO at INBS. \u201cThese new upgrades reflect our commitment to protecting donor data and implementing security measures that meet and exceed regulatory expectations, bolstering our upcoming 510(k) submission to the FDA.” <\/em>\n <\/p>\n

The penetration testing forms part of INBS’s FDA 510(k) submission. By addressing security requirements early in the process, INBS is positioning its technology to meet evolving FDA guidance on medical device cybersecurity. If obtained, FDA clearance will open new revenue and expansion opportunities for the Company in the multi-billion-dollar U.S. drug screening market.<\/p>\n

\n About Intelligent Bio Solutions Inc.<\/strong>\n <\/p>\n

Intelligent Bio Solutions Inc.\u00a0(Nasdaq: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its\u202fIntelligent Fingerprinting Drug Screening System\u202fwill revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in\u00a0additional\u00a0fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company\u2019s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and\u00a0logistics\u00a0firms, mining, drug treatment organizations, and coroners.\u00a0<\/p>\n

For more information, visit:\u202fhttps:\/\/ibs.inc\/<\/a><\/p>\n

\n Forward-Looking Statements\u00a0<\/strong>\n <\/p>\n

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, and\u00a0involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, statements\u00a0regarding\u00a0Intelligent Bio Solutions Inc.\u2019s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefits from its partnerships and collaborations, and secure regulatory clearance or approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, actual results may differ materially from those expressed or implied by such statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including \u201cbelieves,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cprojects,\u201d \u201cintends,\u201d \u201cpotential,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d and \u201capproximately,\u201d or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those described in Intelligent Bio Solutions\u2019 public filings with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of the date of this release. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.\u00a0\u00a0<\/p>\n

\n Company Contact<\/strong>
\n
Intelligent Bio Solutions Inc.
info@ibs.inc<\/a><\/p>\n

\n Investor & Media Contact<\/strong>
\n
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

INBS implements enhanced security architecture to protect test integrity and donor data, strengthening upcoming FDA 510(k) submission NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of penetration testing as part of its upcoming FDA 510(k) submission. The testing identified no major vulnerabilities, verified the robustness of the Company’s existing security infrastructure, and strengthened its regulatory submission to the FDA. In conjunction with the penetration testing, INBS implemented additional security upgrades to its drug testing technology. These upgrades include enhanced encrypted identification tags to ensure test integrity and improved firmware safeguards that allow only authorized updates … <\/p>\n

Continue reading “Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-952514","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nIntelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"INBS implements enhanced security architecture to protect test integrity and donor data, strengthening upcoming FDA 510(k) submission NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of penetration testing as part of its upcoming FDA 510(k) submission. The testing identified no major vulnerabilities, verified the robustness of the Company’s existing security infrastructure, and strengthened its regulatory submission to the FDA. In conjunction with the penetration testing, INBS implemented additional security upgrades to its drug testing technology. These upgrades include enhanced encrypted identification tags to ensure test integrity and improved firmware safeguards that allow only authorized updates … Continue reading "Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-17T12:34:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTU5NSM3NTQwNDAzIzIxODk1NjU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified\",\"datePublished\":\"2026-04-17T12:34:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified\\\/\"},\"wordCount\":660,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MTU5NSM3NTQwNDAzIzIxODk1NjU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified\\\/\",\"name\":\"Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MTU5NSM3NTQwNDAzIzIxODk1NjU=\",\"datePublished\":\"2026-04-17T12:34:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MTU5NSM3NTQwNDAzIzIxODk1NjU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MTU5NSM3NTQwNDAzIzIxODk1NjU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified\/","og_locale":"en_US","og_type":"article","og_title":"Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified - Market Newsdesk","og_description":"INBS implements enhanced security architecture to protect test integrity and donor data, strengthening upcoming FDA 510(k) submission NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of penetration testing as part of its upcoming FDA 510(k) submission. The testing identified no major vulnerabilities, verified the robustness of the Company’s existing security infrastructure, and strengthened its regulatory submission to the FDA. In conjunction with the penetration testing, INBS implemented additional security upgrades to its drug testing technology. These upgrades include enhanced encrypted identification tags to ensure test integrity and improved firmware safeguards that allow only authorized updates … Continue reading \"Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-17T12:34:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTU5NSM3NTQwNDAzIzIxODk1NjU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified","datePublished":"2026-04-17T12:34:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified\/"},"wordCount":660,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTU5NSM3NTQwNDAzIzIxODk1NjU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified\/","name":"Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTU5NSM3NTQwNDAzIzIxODk1NjU=","datePublished":"2026-04-17T12:34:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTU5NSM3NTQwNDAzIzIxODk1NjU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTU5NSM3NTQwNDAzIzIxODk1NjU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-advances-upcoming-fda-510k-submission-successfully-completes-penetration-testing-with-no-major-vulnerabilities-identified\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952514","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=952514"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952514\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=952514"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=952514"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=952514"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}